Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) reported full-year 2025 revenue of RMB 2.08 billion, a year-on-year decline of 26.10% or RMB 736.70 million, driven mainly by a reduction of approximately RMB 720 million in human albumin solution sales volumes.
Gross profit fell RMB 77.80 million to RMB 222.10 million, while gross margin remained stable at 10.70% (2024: 10.60%). Net profit attributable to shareholders decreased 16.90% to RMB 34.90 million, resulting in basic and diluted EPS of RMB 0.017 (2024: RMB 0.021).
Segment performance • Imported pharmaceutical products contributed RMB 2.06 billion in revenue (-26.1%). • Medical beauty services generated RMB 21.03 million (-26.8%). • The aesthetic medicine R&D segment has yet to record revenue but booked a segment loss of RMB 9.37 million.
Operating metrics • Selling and distribution expenses fell 9.93% to RMB 57.57 million. • Administrative expenses dropped 34.32% to RMB 82.75 million, reflecting lower R&D spending and staff costs. • Finance costs doubled to RMB 33.94 million, mainly due to a RMB 12.99 million guarantee fee and higher interest expense.
Balance sheet highlights (31 Dec 2025) • Total assets: RMB 1.85 billion; equity: RMB 694.06 million. • Net current assets improved to RMB 203.18 million (2024: RMB 180.55 million). • Inventories decreased 26.32% to RMB 259.56 million, extending turnover to 60 days (2024: 33 days). • Bank borrowings fell to RMB 179.72 million (2024: RMB 340.91 million); gearing ratio eased to 52.20% (2024: 57.50%). • Cash and cash equivalents stood at RMB 249.20 million; operating activities generated a positive cash inflow of RMB 207.59 million (2024 outflow: RMB 232.88 million).
Dividend The Board proposes a final dividend of HK 0.167 cents per share, totaling approximately HK 3.40 million, pending shareholder approval (2024: HK 0.20 cents).
Operational notes – Nationwide batch releases of human albumin solution declined to roughly 5,212 batches (2024: 5,511), reflecting softer hospital demand amid continued cost-containment measures. – The Chengdu cold-chain facility, Phase I (15,000 sqm), is fully operational, supporting biologics distribution. – The Group submitted launch registration for its first self-developed polycaprolactone filler “Girl Needle Type S” in December 2025.
Looking ahead, management will focus on stabilising market share through participation in volume-based procurement, advancing medical aesthetics R&D, and enhancing cold-chain supply capabilities while maintaining a conservative liquidity position.
Comments